Medical Device Network on MSN2d
Medtronic announces two-year trial outcomes of Evolut TAVRMedtronic has announced the Small Annuli Randomized To Evolut or SAPIEN (SMART) head-to-head comparative trial’s two-year ...
Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...
Zacks Investment Research on MSN2d
Positive Trial Data on Evolut TAVR Likely to Support MDT StockMedtronic plc MDT recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN (“SMART”) Trial results at the Cardiovascular Research Technologies (“CRT”) 2025 conference in Washington, D.C.
Medtronic plc released positive results from a two-year trial of Evolut TAVR that demonstrated superior valve performance in patients with small aortic annuli. The SMall Annuli Randomized To Evolut or ...
Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...
"The two-year results highlight the continued superior performance of the Evolut TAVR valve in these patients. While we would not yet expect to see a significant difference in the composite ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...
The two-year results highlighted the continued superior performance of the Evolut TAVR valve in patients with a small aortic annulus. These results will be followed to assess long-term outcomes.
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMa ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback